



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Khan et al.

Serial No.: 10/821,240

Filed: April 8, 2004

For: METHODS AND USES FOR
PROTEIN BREAKDOWN PRODUCTS

Confirmation No.: 9732

Examiner: R. Negin

Group Art Unit: 1631

Attorney Docket No.: 3077-6384US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV926540668US

Date of Deposit with USPS: December 7, 2006

Person making Deposit: Diane Sanders

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO/SB/08 be considered by the Examiner and made of record. Copies of any cited foreign patents, publications, or pending unpublished U.S. applications are enclosed pursuant to 37 C.F.R. § 1.98(a)(2).

Pursuant to 37 C.F.R. § 1.98(d), a copy of any patent, publication or other information listed in the Information Disclosure Statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. § 120.

Accordingly, no copy of information marked with a pound sign (#) is enclosed because it was previously cited or submitted to the patent office in a prior application which is properly identified, and is relied upon for an earlier filing date. The references are as follows:

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#US - 4,427,660	01-1984	Schiffman et al.
#US - 4,571,336	02-1986	Houck et al.
#US - 4,753,965	06-1988	Stemerick et al.
#US - 4,855,285	08-1989	Stevens
#US - 5,002,961	03-1991	Dage et al.
#US - 5,223,397	06-1993	Pouletty
#US - 5,801,193	09-1998	Ojo-Amaize et al.
#US - 5,854,004	12-1998	Czemilofsky et al.
#US - 5,942,494	08-1999	Ginsberg et al.
#US - 5,972,924	10-1999	Keep et al.
#US - 5,994,126	11-1999	Steinman et al.
#US - 5,981,486	11-1999	Matsushima et al.
#US - 6,051,596	04-2000	Badger
#US - 6,075,150	06-2000	Wang et al.
#US - 6,150,500	11-2000	Salerno
#US - 6,235,281	05-2001	Stenzel et al.
#US - 6,310,041	10-2001	Haddox et al.
#US - 6,361,992	03-2002	Szkudlinski et al.
#US - 2003/0148955	08-2003	Pluenneke
#US - 6,630,138	10-2003	Gerlitz et al.
#US - 6,831,057	12-2004	Baldwin et al.
#US - 6,844,315	01-2005	Khan et al.
#US- 2004/0208885 A1	10-21-2004	Khan et al.
US- 2005/0214943 A1	09-29-2005	Khan et al.

Serial No.: 10/753,510

US- 2005/0227925 A1	10-13-2005	Benner et al.
US- 2006/0111292 A1	05-25-2006	Khan et al.
US- 2006/0142205 A1	06-29-2006	Benner et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#WO 98/34631 A1	08-1998	Thomas Jefferson University
#WO 2001/83554 A2	11-2001	Praecis Pharmaceuticals Incorporated et al.
GB 2 194 886 A	03-23-1988	The Wellcome Foundation Limited

Other Documents

#ABRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.

#ADIB-CONQUY et al., "NF-kappaB Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, Vol. 162.

#ARIMA et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, Vol. 22, No. 3.

#BAEUERLE et al., "Function and Activation of NF-kappaB in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, Vol. 12.

#BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor-kappaB Activation," The Journal of Neuroscience, 1 May 1998, pp. 3251-3260, Vol. 18, No. 9.

#BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" Mental Retardation and Developmental Disabilities Research Reviews, 2004, pp. 318-326, Vol. 10.

#BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-gamma," *Journal of Interferon and Cytokine Research*, 1997, pp. 295-306, Vol. 17.

#CUI et al., *Am. J. Physiol. Integr. Comp. Physiol.*, 2004, pp. R699-R709, Vol. 286.

#DWINNELL et al., *Atlas of Diseases of the Kidney*, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12.

#EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," *Science*, 22 December 1989, pp. 1617-1620, Vol. 246.

#EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," *Oncogene*, 1999, pp. 6896-6909, Vol. 18.

#FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," *Bailliere's Clinical Haematology*, 2000, 179-197, Vol. 13. No. 2.

#JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injury in Rats," *Ann. N.Y Acad. Sci.*, 2005, pp. 148-150, Vol. 1053.

#KALNS et al., *Biochem. Biophys. Res. Comm.*, 2002, pp. 41-44, Vol. 292.

#KALNS et al., *Biochem. Biophys. Res. Comm.*, 2002, pp. 506-09, Vol. 297.

#KIDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," *Alternative Medicine Review*, 2002, pp. 472-499, Vol. 7, No. 6.

#KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," *Am. J. Psychiatry*, May 2000, pp. 683-694, Vol. 157, No. 5.

#LI et al., "NF-kappaB Regulation in the Immune System," *Nature Reviews/Immunology*, October 2002, pp. 725-734, Vol. 2.

#MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," *Drug News Prospects*, June 1998, pp. 271-276, Vol. 11, No. 5.

#MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," *Gen. Pharmac.*, 1998, pp. 431-434, Vol. 30, No. 4.

#MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappaB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.

#Merck Index, 17th ed. 1999, pp. 1145-1146, 1841-1848, 2539, 2551.

#Merriam-Webster Medical Dictionary, 1994, p. 82.

#MOAYERI et al., Journal of Clinical Investigation, September 2003, pp. 670-82, Vol. 112, No. 5.

#NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.

#NGO et al., The protein folding problem and tertiary structure prediction, 1994, pp. 492-94.

#PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462.

#SAMANIEGO et al., "Induction of Programmed Cell Death in Kaposi's Sarcoma Cells by Preparations of Human Chorionic Gonadotropin," Journal of the National Cancer Institute, January 20, 1999, pp. 135-43, Vol. 91, No. 2.

#SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.

#TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.

#WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neutrophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.

#YANG et al., "Increased cortical nuclear factor kappaB (NF-kappaB) DNA binding activity after traumatic brain injury in rats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 10/028,075 Filed: December 21, 2001

For: GENE REGULATOR, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

Serial No.: 10/753,510


This Supplemental Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Allen C. Turner', written over the typed name.

Allen C. Turner
Registration No. 33,041
Attorney for Applicant(s)
TRASKBRITT, P.C.
P.O. Box 2550
Salt Lake City, Utah 84110-2550
Telephone: 801-532-1922

Date: December 7, 2006
ACT/bv
Enclosures: Form PTO/SB/08
Cited Reference



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

4

Complete if Known

Application Number	10/821,240
Filing Date	April 8, 2004
First Named Inventor	Khan et al.
Group Art Unit	1631
Examiner Name	R. Negin
Attorney Docket Number	3077-6384US

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		#US- 4,427,660	01-1984	Schiffman et al.	
		#US- 4,571,336	02-1986	Houck et al.	
		#US- 4,753,965	06-1988	Stemerick et al.	
		#US- 4,855,285	08-1989	Stevens	
		#US- 5,002,961	03-1991	Dage et al.	
		#US- 5,854,004	12-1998	Czenilofsky et al.	
		#US- 5,223,397	06-1993	Pouletty	
		#US- 5,801,193	09-1998	Ojo-Amaize et al.	
		#US- 5,942,494	08-1999	Ginsberg et al.	
		#US- 5,972,924	10-1999	Keep et al.	
		#US- 5,994,126	11-1999	Steinman et al.	
		#US- 5,981,486	11-1999	Matsushima et al.	
		#US- 6,051,596	04-2000	Badger	
		#US- 6,075,150	06-2000	Wang et al.	
		#US- 6,150,500	11-2000	Salerno	
		#US- 6,235,281	05-2001	Stenzel et al.	
		#US- 6,310,041	10-2001	Haddox et al.	
		#US- 6,361,992	03-2002	Szkudlinski et al.	
		#US- 2003/0148955	08-2003	Pluenneke	
		#US- 6,630,138	10-2003	Gerlitz et al.	
		#US- 6,831,057	12-2004	Baldwin et al.	
		#US- 6,844,315	01-2005	Khan et al.	
		#US- 2004/0208885 A1	10-21-2004	Khan et al.	
		US- 2005/0214943 A1	09-29-2005	Khan et al.	
		US- 2005/0227925 A1	10-13-2005	Benner et al.	
		US- 2006/0111292 A1	05-25-2006	Khan et al.	
		US- 2006/0142205 A1	06-29-2006	Benner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		#WO 98/34631 A1	08-1998	Thomas Jefferson University		
		#WO 2001/83554 A2	11-2001	Praecis Pharmaceuticals Incorporated et al.		
		GB 2 194 886 A	03-23-1988	The Wellcome Foundation Limited		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

4

Complete if Known

Application Number	10/821,240
Filing Date	April 8, 2004
First Named Inventor	Khan et al.
Group Art Unit	1631
Examiner Name	R. Negin
Attorney Docket Number	3077-6384US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		#ABRAHAM, E., "Coagulation Abnormalities in Acute Lung Injury and Sepsis," Am. J. Respir. Cell Mol. Biol., 2000, pp. 401-404, Vol. 22.	
		#ADIB-CONQUY et al., "NF-kappaB Expression in Mononuclear Cells in Patients with Sepsis Resembles That Observed in Lipopolysaccharide Tolerance," Am. J. Respir. Crit. Care Med., 2000, pp. 1877-1883, Vol. 162.	
		#ARIMA et al., "IL-2-Induced Growth of CD8+ T Cell Prolymphocytic Leukemia Cells Mediated by NF-kappaB Induction and IL-2 Receptor alpha Expression," Leukemia Research, 1998, pp. 265-273, Vol. 22, No. 3.	
		#BAEUEERLE et al., "Function and Activation of NF-kappaB in the Immune System," Annu. Rev. Immunol., 1994, pp. 141-179, Vol. 12.	
		#BETHEA et al., "Traumatic Spinal Cord Injury Induces Nuclear Factor-kappaB Activation," The Journal of Neuroscience, 1 May 1998, pp. 3251-3260, Vol. 18, No. 9.	
		#BODFISH et al., "Treating the Core Features of Autism: Are We There Yet?" Mental Retardation and Developmental Disabilities Research Reviews, 2004, pp. 318-326, Vol. 10.	
		#BROWN et al., "Two Forms of NF-kappaB1 (p105/p50) in Murine Macrophages: Differential Regulation by Lipopolysaccharide, Interleukin-2, and Interferon-gamma," Journal of Interferon and Cytokine Research, 1997, pp. 295-306, Vol. 17.	
		#CUI et al., Am. J. Physiol. Integr. Comp. Physiol., 2004, pp. R699-R709, Vol. 286.	
		#DWINNELL et al., Atlas of Diseases of the Kidney, Blackwell Sciences, 1999, pp. 12.1-12.12, Ch. 12.	
		#EMMEL et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T Cell Activation," Science, 22 December 1989, pp. 1617-1620, Vol. 246.	
		#EPINAT et al., "Diverse agents act at multiple levels to inhibit the Rel/NF-kappaB signal transduction pathway," Oncogene, 1999, pp. 6896-6909, Vol. 18.	
		#FAUST et al., "Disseminated intravascular coagulation and purpura fulminans secondary to infection," Bailliere's Clinical Haematology, 2000, 179-197, Vol. 13, No. 2.	
		#JIMENEZ-GARZA et al., "Early Effects of Modulating Nuclear factor-kappaB Activation on Traumatic Spinal Cord Injury in Rats," Ann. N.Y. Acad. Sci., 2005, pp. 148-150, Vol. 1053.	
		#KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 41-44, Vol. 292.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet 3 of 4

Complete if Known

Application Number	10/821,240
Filing Date	April 8, 2004
First Named Inventor	Khan et al.
Group Art Unit	1631
Examiner Name	R. Negin
Attorney Docket Number	3077-6384US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		#KALNS et al., Biochem. Biophys. Res. Comm., 2002, pp. 506-09, Vol. 297.	
		#KIDD et al., "Autism, An Extreme Challenge to Integrative Medicine. Part II: Medical Management," Alternative Medicine Review, 2002, pp. 472-499, Vol. 7, No. 6.	
		#KRONFOL et al., "Cytokines and the Brain: Implications for Clinical Psychiatry," Am. J. Psychiatry, May 2000, pp. 683-694, Vol. 157, No. 5.	
		#LI et al., "NF-kappaB Regulation in the Immune System," Nature Reviews/Immunology, October 2002, pp. 725-734, Vol. 2.	
		#MALEK-AHMADI, P., "Role of Cytokines in Psychopathology: Therapeutic Implications," Drug News Prospects, June 1998, pp. 271-276, Vol. 11, No. 5.	
		#MCBEAN et al., "Rodent Models of Global Cerebral Ischemia: A Comparison of Two-Vessel Occlusion and Four-Vessel Occlusion," Gen. Pharmac., 1998, pp. 431-434, Vol. 30, No. 4.	
		#MCDONALD et al., "Interleukin-15 (IL-15) Induces NF-kappaB Activation and IL-8 Production in Human Neutrophils," Blood, 15 December 1998, pp. 4828-4835, Vol. 92, No. 12.	
		#Merck Index, 17th ed. 1999, pp. 1145-1146, 1841-1848, 2539, 2551.	
		#Merriam-Webster Medical Dictionary, 1994, p. 82.	
		#MOAYERI et al., Journal of Clinical Investigation, September 2003, pp. 670-82, Vol. 112, No. 5.	
		#NEELY et al., "Then and now: Studies using a burned mouse model reflect trends in burn research over the past 25 years," Burns, 1999, pp. 603-609, Vol. 25.	
		#NGO et al., The protein folding problem and tertiary structure prediction, 1994, pp. 492-94.	
		#PELLIZZARI et al., FEBS Letters, 1999, pp. 199-204, Vol. 462.	
		#SAMANIEGO et al., Induction of Programmed Cell Death in Kaposi's Sarcoma Cells by Preparations of Human Chorionic Gonadotropin, Journal of the National Cancer Institute, January 20, 1999, pp. 135-43, Vol. 91, No. 2.	
		#SMITH et al., "Recent developments in drug therapy for multiple sclerosis," Multiple Sclerosis, 1999, pp. 110-120, Vol. 5.	
		#TRAYSTMAN, R., "Animal Models of Focal and Global Cerebral Ischemia," ILAR Journal, 2003, pp. 85-95, Vol. 44, No. 2.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(use as many sheets as necessary)*

Sheet

4

of

4

Complete if Known

Application Number	10/821,240
Filing Date	April 8, 2004
First Named Inventor	Khan et al.
Group Art Unit	1631
Examiner Name	R. Negin
Attorney Docket Number	3077-6384US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		#WEINBERGER et al., "Mechanisms Mediating the Biologic Activity of Synthetic Proline, Glycine, and Hydroxyproline Polypeptides in Human Neutrophils," Mediators of Inflammation, 2005, pp. 31-38, Vol. 1.	
		#YANG et al., "Increased cortical nuclear factor kappaB (NF-kappaB) DNA binding activity after traumatic brain injury in rats," Neuroscience Letters, 1995, pp. 101-104, Vol. 197.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 10/028,075

Filed: December 21, 2001

For: GENE REGULATOR, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.